Immuron - FY25 global sales exceed projection, up 49% on prior year

Sales Performance - Immuron Limited reported annual sales of AUD$7.3 million, representing a 49% increase compared to the previous year [1][3] - For the June 2025 quarter, sales reached AUD$2.0 million, up 55% year-over-year [1] - In Australia, annual sales were AUD$5.2 million, a 40% increase from the prior year, with June 2025 quarter sales of AUD$1.5 million, up 58% [1][3] - North American sales totaled AUD$2.0 million, reflecting a 76% increase year-over-year, with June 2025 quarter sales of AUD$0.5 million, up 49% [1][3] Product Overview - Travelan is an over-the-counter immune supplement designed to target pathogenic bacteria and their toxins in the gastrointestinal tract [1][4] - It is an orally administered passive immunotherapy that helps reduce the likelihood of travelers' diarrhea, caused primarily by enterotoxigenic Escherichia coli (ETEC) [4][5] - Travelan is recognized as a listed medicine in Australia and a licensed natural health product in Canada, while in the U.S., it is marketed as a dietary supplement [4] Strategic Focus - The company aims to position Travelan as an essential product for travelers, with a clear growth strategy supporting its sales increase [3] - Immuron plans to invest further in North America while maintaining momentum in the Australian market [3]